DS-1471
/ Daiichi Sankyo
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
August 23, 2025
DS1471-079: A Study of DS-1471a In Subjects With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=17 | Terminated | Sponsor: Daiichi Sankyo Co., Ltd. | N=80 ➔ 17 | Trial completion date: Jun 2027 ➔ Jul 2025 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2027 ➔ Jul 2025; The study was terminated by the sponsor due to a business decision.
Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Oncology • Solid Tumor
July 25, 2024
A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
(ESMO 2024)
- P1 | "Safety measures for primary outcomes in this study include dose-limiting toxicities and treatment-emergent adverse events. Secondary outcome measures for both parts include best overall response, time to response, duration of response, progression-free survival, and overall survival."
Clinical • Metastases • P1 data • Oncology • Solid Tumor • BSG
October 10, 2023
A Study of DS-1471a In Subjects With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=80 | Recruiting | Sponsor: Daiichi Sankyo Co., Ltd.
Metastases • New P1 trial • Gastrointestinal Cancer • Oncology • Solid Tumor
September 16, 2023
Preclinical pharmacokinetic-pharmacodynamic modeling guides setting of the human starting dose of DS-1471a, a novel anti-CD147 antibody.
(AACR-NCI-EORTC 2023)
- No abstract available
PK/PD data • Preclinical • Oncology
September 16, 2023
Novel Anti-CD147 Antibody DS-1471a Exerts Antitumor Effect in Hepatocellular Carcinoma Patient Derived Xenograft Models and its Efficacy Correlates with the Expression of CD147.
(AACR-NCI-EORTC 2023)
- No abstract available
Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor
1 to 5
Of
5
Go to page
1